Table 1. Expressions of CK19, galectin-3, VEGF, and EGFR in papillary thyroid carcinoma and thyroid papillary hyperplasia.
| Tissue | n | CK19 |
Positive rate (%) | Galectin-3 |
Positive rate (%) | VEGF |
Positive rate (%) | EGFR | Positive rate (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (-) | (+) | (++) | (+++) | (-) | (+) | (++) | (+++) | (-) | (+) | (++) | (+++) | (-) | (+) | (++) | (+++) | ||||||
| Thyroid papillary hyperplasia | 12 | 11 | 1 | 0 | 0 | (9.1)* | 10 | 2 | 0 | 0 | (16.7)* | 9 | 1 | 2 | 0 | (25.0)* | 10 | 2 | 0 | 0 | (20.0)* |
| Papillary thyroid carcinoma | 38 | 0 | 0 | 12 | 26 | (100) | 1 | 1 | 22 | 14 | (97.4) | 8 | 4 | 18 | 8 | (78.9) | 10 | 3 | 15 | 10 | (73.7) |
| With lymph node metastasis | 6 | 0 | 0 | 2 | 4 | (100) | 0 | 0 | 1 | 5 | (100) | 1 | 2 | 3 | 0 | (83.3) | 1 | 3 | 2 | 0 | (83.3) |
| Without lymph node metastasis | 32 | 0 | 0 | 10 | 22 | (100) | 1 | 1 | 21 | 9 | (96.9) | 7 | 2 | 15 | 8 | (78.1)** | 9 | 0 | 13 | 10 | (71.9)** |
Note: *P<0.05, compared with papillary thyroid carcinoma group; **P<0.05, compared with “with lymph node metastasis” group.